SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
6 references·0 citing·29 second hopsampled
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis (2019)Nivolumab Versus Docetaxel for Previously…First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma (2019)First-line Nivolumab Plus Ipi…The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment (2018)The financial burden and dist…Health state utilities in non–small cell lung cancer: An international study (2016)Health state utilities in non…Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy (2014)Cost-effectiveness analysis o…Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting (2012)Economic Evaluation of First-…Improved curve fits to summary survival data: application to economic evaluation of health technologies (2011)Improved curve fits to summar…Development of WHO guidelines on generalized cost-effectiveness analysis (2000)Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)China's health system and its reform: a review of recent studies (2009)Economic evaluation of nivolumab as a second‐line treatment for advanced renal cell carcinoma from US and C hinese perspectives (2017)Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC (2020)Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints (1998)Decision Modelling For Health Economic Evaluation (2006)Practical methods for incorporating summary time-to-event data into meta-analysis (2007)Overview of Parametric Survival Analysis for Health-Economic Applications (2013)Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? (2020)A utility maximization model for evaluation of health care programs. (1972)Utility approach to measuring health-related quality of life (1987)Health state utilities for non small cell lung cancer (2008)First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis (2019)Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (2021)Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations (2021)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer (2016)Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) (2016)Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications (2019)Financial toxicity in cancer care: origins, impact, and solutions (2021)Navigating financial toxicity in patients with cancer: A multidisciplinary management approach (2022)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer (2020)Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer (2021)United States Life Tables, 2021 (2023)Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China (2018)Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma (2020)Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China (2021)
this work references cited by second hop· second hop is a sample of the most-cited connections

References

  • 2018The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment873 cited
  • 2011Improved curve fits to summary survival data: application to economic evaluation of health technologies308 cited
  • 2016Health state utilities in non–small cell lung cancer: An international study304 cited
  • 2019First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma150 cited
  • 2012Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting108 cited
  • 2014Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy72 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work